🔬 Nasus Pharma Announces Transition of Chief Financial
Published by OOPSONLINE.IN · Source: The Manila Times · 1 min read · · Updated
What actually happened
TEL AVIV, Israel, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE American: NSRX) ('Nasus', 'Nasus Pharma” or the 'Company'), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry. Mr. Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition. Oren Elmaliach, the Company’s Director of Finance, has been appoi
Key points
- TEL AVIV, Israel, Aug.
- 19, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd.
- (NYSE American: NSRX) ('Nasus', 'Nasus Pharma” or the 'Company'), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Chief Financial Officer, Eyal Rubin, will be leaving the Company to pursue a new opportunity outside of the life science industry.
- Rubin will remain with Nasus through September 18, 2026, and will work closely with the Company to ensure a seamless and orderly transition.
Summary based on data provided by The Manila Times. Full article available at the original publisher.
- #science
- #nasus
- #pharma